On this episode of the Endpoints, Dr. Steve Perrin, CEO at ALS TDI answers questions about one of the most talked about clinical trials in ALS at the moment, Brainstorm Cell Therapeutics’ NurOwn, a proposed stem-cell-based treatment. The therapy focuses on the cellular support system around a person with ALS’ motor neurons. It aims to slow disease progression by replacing the damaged system with an enhanced one.

To listen to more episodes of the Endpoints Podcast, click here.

Support the show: https://www.als.net/donate/

See omnystudio.com/listener for privacy information.